stress, brain activity, cardiovascular risk, PET-CT, MGH, ISSMS, The Lancet study
News | Neuro Imaging | January 18, 2017

A study led by Massachusetts General Hospital (MGH) and Icahn School of Medicine at Mount Sinai (ISSMS)...

News | Radiopharmaceuticals and Tracers | January 17, 2017

NorthStar Medical Technologies LLC has received additional matching funds from the U.S. Department of Energy’s ...

metastatic colorectal cancer, mCRC, Sirtex, NCCN guidelines, Y-90 microspheres
News | Radiation Therapy | January 03, 2017

Sirtex Medical Limited announced in December that SIR-Spheres Y-90 resin microspheres have been included as a...

SNMMI Develops USP Recommendations for Compounded Sterile Radiopharmaceuticals
News | December 28, 2016

December 28, 2016 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has developed United States...

prostate, CT scan
News | Prostate Cancer | December 22, 2016

Cancer Targeted Technology (CTT), a privately-held Seattle-based biotechnology firm focusing on cancer diagnostics...

News | Prostate Cancer | December 14, 2016

Cancer Targeted Technology (CTT), a privately-held Seattle-based biotechnology firm focusing on small molecules that...

News | Nuclear Imaging | December 12, 2016

Molecular Targeting Technologies, Inc. (MTTI) announces that response of colorectal cancer to treatment can be...

Numa, NumaStatus, radiation dose reporting software, RSNA 2016
News | Radiation Dose Management | December 08, 2016

Numa introduced a new software application at the 2016 Annual Meeting of the Radiological Society of North America (...

PET, F-18 florbetaben, cardiac amyloidosis, Princess Alexandria Hospital

In a pilot study, F-18-florbetaben PET imaging appeared promising for differentiating between cardiac amyloidosis and hypertensive heart disease. Image courtesy of W. Phillip Law/Princess Alexandra Hospital, Brisbane, Australia. 

News | Nuclear Imaging | December 06, 2016

Researchers at Princess Alexandra Hospital, Brisbane, Australia, have demonstrated that cardiac amyloidosis (...

xSPECT Quant technology, SPECT/CT, Symbia Intevo, Siemens Healthineers, RSNA 2016
News | SPECT Imaging | December 06, 2016

December 6, 2016 — At the 102nd Scientific Assembly and Annual Meeting of the Radiological Society of North America...

prostate cancer, PET imaging, Johns Hopkins, Daniel Thorek, 11B6 antibody

Uptake of 89Zr-11B6 in the prostate of a transgenic mouse with prostate cancer. Image courtesy of Daniel Thorek

News | Prostate Cancer | November 30, 2016

An international group of researchers report success in mice of a method of using positron emission tomography (PET...

Dilon Diagnostics, GE Healthcare, RSNA 2016, Discovery NM750b molecular breast imaging system, biopsy accessory, FDA clearance
Technology | Breast Imaging | November 28, 2016

November 28, 2016 — Dilon Diagnostics and GE Healthcare announced the U.S.

GE Healthcare, Dilon Diagnostics, North America distribution agreement, Discovery NM750b molecular breast imaging system
News | Women's Health | November 16, 2016

Dilon Diagnostics and GE Healthcare announced the signing of an agreement for Dilon to be the exclusive distributor...

Medic Vision, 2016 growth, RSNA, dose management, reporting, SafeCT
News | Radiation Dose Management | November 10, 2016

Medic Vision Imaging Solutions Ltd. announced recently that the company has tripled its growth. Fueled by compliance...

radiology outcomes

Graphic courtesy of Pixabay

Blog | Imaging | November 09, 2016

Much has been said about the potential of outcomes to change the practice of medicine. Through comparative studies,...

LumaGEM molecular breast imaging system, MBI, Gamma Medica, Henry Ford Health System, RSNA 2016
News | Breast Imaging | November 07, 2016

Gamma Medica announced that Henry Ford Health System (Detroit) has purchased Gamma Medica’s LumaGEM Molecular Breast...

Alzheimer's disease, early diagnosis, PET scans, imaging compound, Fluselenamyl

Researchers at Washington University School of Medicine in St. Louis have developed a chemical compound that detects the Alzheimer’s protein amyloid beta better than current FDA-approved agents. The compound potentially may be used in brain scans to identify people in the earliest stages of Alzheimer’s disease. In the image, the compound has passed from the bloodstream of a living mouse into its brain, where it is detected by a positron emission tomography (PET) scan. Arrows indicate clumps of amyloid beta. Credit Ping Yan and Jin-Moo Lee.

News | Radiopharmaceuticals and Tracers | November 02, 2016

November 2, 2016 — By the time unambiguous signs of memory loss and cognitive decline appear in people with...

PET/CT, atherosclerotic plaque detection, Stanford University

Application of dual-modality optical and PET/CT activity-based probe in experimental carotid inflammation model. Coronal noninvasive PET/CT scans of (A) healthy and (B) diseased mice with and without ligated carotid arteries respectively. Inset images show optical ex vivo florescence imagining of (A) healthy and (B) diseased carotid arteries.  PET/CT and optical images courtesy of Xiaowei Ma, Toshinobu Saito and Nimali Withana.

News | PET-CT | November 01, 2016

Researchers at Stanford University have demonstrated for the first time the use of a dual optical and positron...

NAS report, National Academies of Sciences Engineering and Medicine, Mo-99 production, highly enriched uranium, HEU, SNMMI
News | Radiopharmaceuticals and Tracers | October 28, 2016

The National Academies of Sciences, Engineering, and Medicine (NAS) have released a report on the state of...

Axumin, fluciclovine F-18, PET agent, Phase 3 study, recurrent prostate cancer detection, Blue Earth Diagnostics
News | Prostate Cancer | October 25, 2016

Blue Earth Diagnostics Ltd. announced the peer-reviewed publication of results from a Phase 3 clinical trial of...

Overlay Init